ABSTRACT

Introduction

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly grown into a public health emergency that has placed the national health systems as well as scientific research communities under enormous pressures. Drug repurposing or repositioning is a well-known strategy that seeks to deploy existing licensed drugs for newer indications and provides the quickest possible transition from bench to clinics for unmet therapeutic needs. Given the current, urgent, and dire need for effective therapies against novel coronavirus-19, this approach is particularly appealing.

Areas covered

Here, we review the significant anti-inflammatory, immunomodulatory, and antiviral properties of minocycline as potential mechanisms for efficacy against the novel coronavirus and highlight the promises and pitfalls of this approach.

Expert opinion

As compared to other agents being investigated for COVID-19, minocycline offers distinct advantages in terms of potential efficacy in patients with life-threatening acute respiratory distress syndrome (ARDS) and myocardial injury, well-known safety and interaction profile, relatively low costs, and widespread availability. We call upon public and private funders to facilitate urgent and rigorous research efforts before evidence-based recommendations for its widespread use can be made.

中文翻译：

---

将美满霉素用于COVID-19管理：机制，机遇和挑战。

摘要

介绍

由严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）引起的2019年冠状病毒病（COVID-19）大流行已迅速发展为公共卫生突发事件，使国家卫生系统和科研界处于巨大压力之下压力。药物重新定位或重新定位是一种众所周知的策略，其目的是部署现有的许可药物以用于较新的适应症，并为满足未满足的治疗需求提供从实验室到诊所的最快过渡。鉴于目前迫切需要针对新型冠状病毒19的有效疗法，这种方法特别有吸引力。

覆盖区域

在这里，我们审查了米诺环素的重要抗炎，免疫调节和抗病毒特性，作为针对新型冠状病毒的潜在疗效机制，并强调了该方法的前景和陷阱。

专家意见

与正在研究COVID-19的其他药物相比，米诺环素在威胁生命的急性呼吸窘迫综合征（ARDS）和心肌损伤的患者的潜在疗效，众所周知的安全性和相互作用特征，相对较低的费用，和广泛的可用性。我们呼吁公共和私人出资者在进行广泛应用的循证医学建议之前，促进紧急和严格的研究工作。